Patients with inflammatory diseases in the United States continue to wait for the availability of a biosimilar etanercept, despite the 2016 approval of Erelzi and the 2019 approval of Eticovo. However, in the European context, biosimilar etanercept is already available, and recently presented data demonstrate that, in some countries, use of the biosimilar is high and making an impact on healthcare costs.
Patients with inflammatory diseases in the United States continue to wait for the availability of a biosimilar etanercept, despite the 2016 approval of Erelzi and the 2019 approval of Eticovo.
However, in the European context, biosimilar etanercept is already available, and recently presented data demonstrate that, in some countries, use of the biosimilar is high and making an impact on healthcare costs.
In Norway, which is among the countries that has been the most aggressive in controlling healthcare expenditures on pharmaceuticals through the use of price regulation and substitution, multiple data registries are available that can be used to track biosimilar use.
A team of investigators used these Norwegian databases to study all patients who were receiving maintenance therapy with etanercept for 9 months before biosimilar availability who then switched to the biosimilar.1 In total, 4799 patients were included.
A total of 70.5% of reference etanercept users were switched to biosimilar SB4 (sold as Benepali in Europe, approved as Eticovo in the United States) from the originator, while 5.7% of patients switched to a different drug altogether after biosimilar availability. For patients who switched to the biosimilar, at 18 months, drug survival was 72% (95% CI, 65%-79%).
The investigators will continue to follow these patients, and at 2 years, drug survival in those who switched will be matched with historic drug survival rates estimated from existing data to provide further insight.
Other European nations have had different levels of biosimilar use, including Spain, where individual, self-governing regions make decisions on strategic plans regarding the choice of products.
Data recently presented from a study of patients in a tertiary hospital in the Murcia region of Spain show that in a setting where switching to biosimilar etanercept was conducted only after gaining patient agreement, substantial cost savings were still possible.2
The study relied on a registry of 133 patients treated in the rheumatology department of the single center, 56 of whom were consulted about switching to the biosimilar. Eventually, 55% of those consulted made the switch after agreeing to use the biosimilar.
Among the patients who did not switch, reasons included moderate or high disease activity, remission, or lack of acceptance of the switch.
According to the researchers, annual costs per patient were €9143.16 (US $10,255.65) for originator etanercept versus €6095.44 (US $6837.10) for the biosimilar, for a total cost savings for all switched patients of €94,479.32 (US $105,975.09).
References
1. Smastuen MC, Madla R, Solli O, Hjelvin E. Retrospective analysis of prescription dynamics of etanercept after introduction of biosimilars based on Norwegian prescription database. an interim analysis. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019; June 12-15, 2019; Madrid, Spain. Abstract OP0311.
2. Dayer PVC, Sara JR, Belando CG, et al. Switching of etanercept in a monographic consultation of biosimilar clinical practice and economic cost. Presented at: The European League Against Rheumatism European Congress of Rheumatology 2019; June 12-15, 2019; Madrid, Spain. Abstract AB1202.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.